Drug Profile
ILS 920
Alternative Names: ILS-920; WAY-265920Latest Information Update: 27 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Neuroprotectants
- Mechanism of Action Immunophilin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer